Cuvinte-cheie (6): tildrakizumab (1), interleukin-23 (1), high-affinity humanized IgG1k antibody (1)
Scopus Author IDPublicaţii peste hotare - 1.
- 4. Articole în reviste de peste hotare
- 4.3.Articole în alte reviste științifice de peste hotare - 1
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis ![]() ![]() ![]() |
Khalilieh Sauzanne1 , Hussain Azher1 , Montgomery Diana1 , Levine Vanessa1 , Shaw Peter Martin1 , Bodrug Inga2 , Mekokishvili Lally3 , Bailey-Smith Candice1 , Glasgow Xiaoli Shirley1 , Cheng Amy1 , Martinho Monika1 , Iwamoto Marian1 |
1 Merck and Co., Inc., Kenilworth, 2 F.C.E. ARENSIA Exploratory Medicine, 3 ARENSIA Exploratory Medicine LLC |
British Journal of Clinical Pharmacology |
Vol. 84, / 2018 / ISSN 0306-5251 |
Disponibil online 5 December, 2018. Descarcări-0. Vizualizări-765 |